Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas
{{output}}
Background: The World Health Organization (WHO) Classification of Tumors of the Central Nervous System (2021) defines lower-grade (WHO grade II/III) isocitrate dehydrogenase (IDH) wild-type astrocytoma as glioblastoma, IDH-wildty... ...
